by Dr. John Briffa
for The Cholesterol Truth

As a population we’re living longer. Generally speaking, older individuals are more prone to chronic conditions such as heart disease. With statin drugs continuing to be a mainstream mainstay in the prevention of heart disease, the elderly represent a growing market for these drugs. While this may be lucrative for pharmaceutical companies, are there any real benefits to be had from prescribing statins to elderly individuals?

One of the most significant trials of statin therapy in the elderly is known as the PROSPER study [1]. In this study, almost 6,000 men and women aged 70-82 were treated with a statin (pravastatin) or placebo for over three years. Each of the individuals in this trial had either a history of cardiovascular disease (e.g. a previous heart attack) or significant risk factors for cardiovascular disease. In this sense, the individuals were deemed to be at relatively high risk of cardiovascular events such as heart attack or stroke. This is relevant as relatively high-risk individuals stand to gain more from statin therapy compared to low-risk individuals. Risk reduction of non-fatal and fatal heart attacks (added together) was 19 per cent in the group taking the statin. Stroke incidence was not affected. Cancer rates were 25 per cent higher in the group taking pravastatin.

Read the Full Article here: http://www.thecholesteroltruth.com/statins-associated-with-significantly-increas

We Lost the War on Cancer – Review of Alternative Cancer Therapies

eBook
Retail : $9⁹⁹
Now : $5⁹⁹

We have lost the war on cancer. At the beginning of the last century, one person in twenty would get cancer. In the 1940s it was one out of every sixteen people. In the 1970s it was one person out of ten. Today one person out of three gets cancer in the course of their life.

The cancer industry is probably the most prosperous business in the United States. In 2014, there will be an estimated 1,665,540 new cancer cases diagnosed and 585,720 cancer deaths in the US. $6 billion of tax-payer funds are cycled through various federal agencies for cancer research, such as the National Cancer Institute (NCI). The NCI states that the medical costs of cancer care are $125 billion, with a projected 39 percent increase to $173 billion by 2020.

The simple fact is that the cancer industry employs too many people and produces too much income to allow a cure to be found. All of the current research on cancer drugs is based on the premise that the cancer market will grow, not shrink.

John Thomas explains to us why the current cancer industry prospers while treating cancer, but cannot afford to cure it in Part I. In Part II, he surveys the various alternative cancer therapies that have been proven effective, but that are not approved by the FDA.